Download MendeleyPotent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor.
Dussupt, V., Sankhala, R.S., Gromowski, G.D., Donofrio, G., De La Barrera, R.A., Larocca, R.A., Zaky, W., Mendez-Rivera, L., Choe, M., Davidson, E., McCracken, M.K., Brien, J.D., Abbink, P., Bai, H., Bryan, A.L., Bias, C.H., Berry, I.M., Botero, N., Cook, T., Doria-Rose, N.A., Escuer, A.G.I., Frimpong, J.A., Geretz, A., Hernandez, M., Hollidge, B.S., Jian, N., Kabra, K., Leggat, D.J., Liu, J., Pinto, A.K., Rutvisuttinunt, W., Setliff, I., Tran, U., Townsley, S., Doranz, B.J., Rolland, M., McDermott, A.B., Georgiev, I.S., Thomas, R., Robb, M.L., Eckels, K.H., Barranco, E., Koren, M., Smith, D.R., Jarman, R.G., George, S.L., Stephenson, K.E., Barouch, D.H., Modjarrad, K., Michael, N.L., Joyce, M.G., Krebs, S.J.(2020) Nat Med 26: 228-235
- PubMed: 32015557
- DOI: https://doi.org/10.1038/s41591-019-0746-2
- Primary Citation of Related Structures:
6MTX, 6MTY, 6NIP, 6NIS, 6NIU - PubMed Abstract:
Zika virus (ZIKV) has caused significant disease, with widespread cases of neurological pathology and congenital neurologic defects. Rapid vaccine development has led to a number of candidates capable of eliciting potent ZIKV-neutralizing antibodies (reviewed in refs. 1-3 ). Despite advances in vaccine development, it remains unclear how ZIKV vaccination affects immune responses in humans with prior flavivirus immunity. Here we show that a single-dose immunization of ZIKV purified inactivated vaccine (ZPIV) 4-7 in a dengue virus (DENV)-experienced human elicited potent cross-neutralizing antibodies to both ZIKV and DENV. Using a unique ZIKV virion-based sorting strategy, we isolated and characterized multiple antibodies, including one termed MZ4, which targets a novel site of vulnerability centered on the Envelope (E) domain I/III linker region and protects mice from viremia and viral dissemination following ZIKV or DENV-2 challenge. These data demonstrate that Zika vaccination in a DENV-experienced individual can boost pre-existing flavivirus immunity and elicit protective responses against both ZIKV and DENV. ZPIV vaccination in Puerto Rican individuals with prior flavivirus experience yielded similar cross-neutralizing potency after a single vaccination, highlighting the potential benefit of ZIKV vaccination in flavivirus-endemic areas.
Organizational Affiliation:
Emerging Infectious Diseases Branch, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
